This report is a thorough analysis of the application of Article 82 EC to supply restrictions It first explains in detail the functioning and regulatory framework of the pharmaceutical market; and after it details why it should be applied on the grounds abuse of dominance. The assessment concludes that competition law should be equally valid in the pharmaceutical sector, and any refusal of limitation of supply that restricts parallel distribution is abusive.